ReviewBiomolecules2026
Theranostic Imaging Agents: Integrating Molecular Diagnostics, Precision Therapeutics, and Artificial Intelligence.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Theranostic imaging agents combine molecular diagnosis, targeted therapy and monitoring of treatment response into a single paradigm of precision medicine. This review summarizes the current development and translational landscape of theranostic imaging agents, covering molecular targets, imaging platforms, principles of agent design, nanotheranostics, radiotheranostics, and disease-specific applications. Particular emphasis is given to clinically validated and emerging targeting strategies using prostate-specific membrane antigen, somatostatin receptors, fibroblast activation protein, C-X-C Chemokine Receptor 4 (CXCR4), Human Epidermal Growth Factor Receptor 2 (HER2) and other disease-associated biomarkers. Moreover, the review addresses Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), Magnetic Resonance Imaging (MRI), optical, photoacoustic, Raman and multimodal imaging approaches, therapeutic payloads, stimulus-responsive systems, and pharmacokinetic optimization. Moreover, emerging applications of artificial intelligence, radiomics, radiogenomics, spatial and single-cell multiomics, liquid biopsy, digital pathology, personalized dosimetry, and digital twins are evaluated for their potential to improve patient stratification, treatment selection, response assessment and adaptive therapy. Despite tremendous progress, clinical translation is hampered by target heterogeneity, off-target accumulation, radionuclide availability, manufacturing complexity, dosimetric uncertainty, regulatory requirements, limited clinical validation, data interoperability, cost and unequal access. This review, overall, emphasizes the convergence of molecular imaging, targeted therapeutics, nanotechnology, and artificial intelligence in the development of next-generation theranostic platforms, and outlines critical priorities for their clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.